Spero Therapeutics earnings were $7.4M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest SPRO earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$9.6M, up 32.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, SPRO reported annual earnings of $8.6M, with -112.5% growth.
SPRO past earnings growth
How has SPRO's earnings growth performed historically?
What were Spero Therapeutics's earnings last quarter?
On SPRO's earnings call on Aug 12, 2026, Spero Therapeutics (NASDAQ: SPRO) reported Q2 2026 earnings per share (EPS) of -$0.16, up 433.33% year over year. Total SPRO earnings for the quarter were -$9.55 million. In the same quarter last year, Spero Therapeutics's earnings per share (EPS) was -$0.03.
As of the last Spero Therapeutics earnings report, Spero Therapeutics is currently profitable. Spero Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $7.38 million, a 113.77% decrease year over year.
What was SPRO's earnings growth in the past year?
As of Spero Therapeutics's earnings date in Aug 12, 2026, Spero Therapeutics's earnings has grown year over year. SPRO earnings in the past year totalled $7.38 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.